Lpath to Present Data at Arrowhead's 3rd Annual Traumatic Brain Injury Conference on March 7, 2013

Lpath to Present Data at Arrowhead's 3rd Annual Traumatic Brain Injury 
Conference on March 7, 2013 
SAN DIEGO, CA -- (Marketwire) -- 02/25/13 --  Lpath, Inc. (NASDAQ:
LPTN), the industry leader in bioactive lipid-targeted therapeutics,
has been invited to present data from its Lpathomab(TM) program in
models of central nervous system injury, including traumatic brain
injury (TBI), at Arrowhead's 3rd Annual Traumatic Brain Injury
Lpathomab is a first-in-class monoclonal antibody that binds to and
neutralizes lysophosphatidic acid (LPA), a bioactive lipid that has
been implicated in neuropathic pain, neurotrauma, and various other
Lpath's vice president and founder, Roger Sabbadini, Ph.D., will
present at the Sheraton Crystal City Hotel in Washington, DC on March
7, 2013, at 11:15 a.m. Eastern time. He will discuss a study
entitled, "Monoclonal Anti-lysophosphatidic Acid Antibodies Are
Neuroprotective after Experimental TBI." The study is part of a
collaboration between Lpath and scientists at the University of
Melbourne (Alice Pebay, Ph.D. and Peter Crack, Ph.D.), UCLA Brain
Injury Research Center (Neil Harris, Ph.D.), and University of
Kentucky (Andrew Morris, Ph.D.). 
The presentation will demonstrate that: (i) LPA receptors are
increased after human brain injury; (ii) LPA levels are upregulated
in the cerebrospinal fluid of TBI patients; (iii) Lpathomab
administered systemically (single dose post-injury) in mouse models
of TBI provides 50+% neuroprotection; and (iv) a single dose of
Lpathomab administered two hours post-injury improves neurobehavioral
outcomes with functional endpoints.  
The data to be presented strongly suggest that LPA
dysregulation/upregulation is causal to injury progression following
TBI and that interventions to reduce LPA might have a significant
impact in mitigating early and late phases of neurotrauma. As such,
Lpathomab could satisfy a critical unmet need by limiting the initial
neuronal damage and inflammatory processes post-TBI, while
subsequently stimulating regenerative processes to optimize long-term
functional outcomes after neurotrauma.  
Lpath is also pursuing LPA as a novel biomarker for TBI.  
According to the conference website (www.tbiconference.com),
"Treatment of TBI and especially acute TBI is still a major unmet
medical need. Therapies that prove an ability to limit the damage
done to the brain and improve clinical outcomes of patients of TBI
will have a major impact on the global pharmaceutical market.
Although past clinical trials for new therapies have ended in
failure, there is indeed renewed interest in this field and with
recent initiatives from both the U.S. Congress and Department of
Defense to improve treatment options for TBI patients, the time has
come for a rethinking of the potential for pharmaceutical management
of this condition." 
About Lpath
 San Diego-based Lpath, Inc., a therapeutic antibody
company, is the category leader in lipid-targeted therapeutics. The
company's ImmuneY2(TM) drug-discovery engine has the unique ability
to generate monoclonal antibodies that bind to and inhibit bioactive
lipids that contribute to disease. The company is developing three
drug candidates: iSONEP(TM) is in a Phase 2 trial for wet AMD;
ASONEP(TM) is in a Phase 2 trial in Renal Cell Carcinoma patients;
and Lpathomab is a preclinical drug candidate that holds promise in
pain, neurotrauma, and other diseases. 
Lpath, Inc.
Scott R. Pancoast
President & CEO
(858) 926-3200
Lpath Investor Relations
Liolios Group, Inc. 
(949) 574-3860
Ron Both: ron@liolios.com
Geoffrey Plank: geoffrey@liolios.com 
Press spacebar to pause and continue. Press esc to stop.